Logo

TPST

Tempest Therapeutics, Inc.

TPST

Tempest Therapeutics, Inc. • NASDAQ
$3.20 ▼ -0.31% (-0.01)
Market Cap $14.21 M
52w High $13.65
52w Low $3.01
Dividend Yield 0%
P/E -0.33
Volume 159.47K
Outstanding Shares 4.44M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $3.531M ▼ $-3.511M ▲ 0% $-0.79 ▲ $-3.445M ▲
Q2-2025 $0 $7.899M ▼ $-7.87M ▲ 0% $-2.07 ▲ $-7.757M ▲
Q1-2025 $0 $10.936M ▼ $-10.86M ▲ 0% $-3.16 ▼ $-10.631M ▲
Q4-2024 $0 $13.918M ▲ $-13.813M ▼ 0% $-0.5 ▼ $-13.517M ▼
Q3-2024 $0 $10.551M $-10.556M 0% $-0.41 $-10.13M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $7.514M ▼ $17.129M ▼ $10.783M ▼ $6.346M ▼
Q2-2025 $14.28M ▼ $24.484M ▼ $14.701M ▼ $9.783M ▼
Q1-2025 $21.511M ▼ $32.164M ▼ $21.031M ▼ $11.133M ▼
Q4-2024 $30.268M ▲ $41.488M ▲ $22.362M ▼ $19.126M ▲
Q3-2024 $22.116M $33.836M $22.379M $11.457M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-3.511M ▲ $-6.779M ▲ $0 $13K ▼ $-6.766M ▲ $-6.779M ▲
Q2-2025 $-7.87M ▲ $-8.431M ▼ $0 $1.2M ▲ $-7.231M ▲ $-8.431M ▼
Q1-2025 $-10.86M ▲ $-8.036M ▲ $0 ▲ $-721K ▼ $-8.757M ▼ $-8.036M ▲
Q4-2024 $-13.813M ▼ $-10.149M ▲ $-3K ▲ $17.952M ▲ $7.8M ▲ $-10.152M ▲
Q3-2024 $-10.556M $-10.182M $-15K $1.541M $-8.656M $-10.197M

Five-Year Company Overview

Income Statement

Income Statement Tempest is still a pure R&D-stage biotech: it has not generated product revenue over the past several years, so all reported results are driven by research and operating expenses. Losses have been steady each year, reflecting ongoing investment in clinical trials and overhead rather than any deterioration in the core business. Per‑share losses look extreme because of multiple reverse stock splits, not because of a sudden collapse in performance. Overall, the income statement shows a typical early‑stage biotech profile: consistent operating losses, no commercial income yet, and results that will be driven by trial outcomes rather than near‑term sales execution.

Balance Sheet

Balance Sheet The balance sheet is small and lean, with total assets modest in size and largely made up of cash. Debt exists but is also relatively limited, suggesting some financial leverage but not an outsized burden. Shareholders’ equity has moved from negative to slightly positive territory in recent years, indicating that capital raises and balance‑sheet clean‑up have helped, but the cushion is still thin. In practical terms, the company appears adequately capitalized for a small biotech today, yet remains sensitive to funding conditions and clinical news given its narrow asset base.

Cash Flow

Cash Flow Cash flows tell a clear story: money is consistently flowing out to fund operations, especially research and development, with no offsetting inflows from product sales. Operating and free cash flow are both negative and of similar size, since the company spends essentially nothing on heavy equipment or facilities. This means cash burn is driven almost entirely by people, trials, and external services. Tempest is reliant on equity raises, partnerships, or other financing to replenish cash, which is typical for a company at this stage but underscores dependence on capital markets and strategic deals.

Competitive Edge

Competitive Edge Tempest’s edge lies in being early and differentiated in a few specific cancer pathways while also branching into cell therapy. Its main drug candidates target mechanisms that are not yet crowded with competitors, and some carry favorable regulatory labels such as orphan and fast‑track status, which can translate into faster reviews and longer market protection if approvals come. The recent expansion into dual‑targeting CAR‑T therapy adds a second technology pillar and more optionality. At the same time, the company is very small and operates in oncology, one of the most competitive areas in pharma, facing large, well‑funded rivals and many parallel programs. Its ultimate competitive strength will likely depend on the quality of its clinical data and its ability to secure strong partners rather than on scale or brand.

Innovation and R&D

Innovation and R&D Innovation is the clear centerpiece of Tempest’s story. The pipeline combines novel small molecules that reshape tumor metabolism and immune responses with next‑generation CAR‑T therapies that hit more than one target to reduce resistance. Lead programs include a first‑in‑class PPAR‑alpha inhibitor in liver cancer, a dual receptor antagonist aimed at preventing colon cancer in high‑risk genetic patients, and a dual‑target CAR‑T for difficult blood cancers. Early clinical results and external support, such as planned NCI‑funded studies, suggest scientific interest in the approach. New preclinical assets, like a T‑cell activator, show that the discovery engine is still active. The flip side is that most programs are still in early or mid‑stage trials, with long timelines, high attrition risk, and substantial funding needs before any commercial payoff.

Summary

Tempest Therapeutics is a classic high‑risk, high‑potential clinical‑stage biotech. Financially, it remains pre‑revenue, runs steady operating losses, and relies on external capital to fund its work, with only a modest balance‑sheet cushion. Strategically, it has built a focused yet diversified oncology pipeline spanning first‑in‑class small molecules and dual‑target CAR‑T therapies, supported by favorable regulatory designations and some non‑dilutive funding prospects. The company’s future will be defined by three things: whether its trials can confirm the early promise of its drugs, whether it can attract and execute strong partnerships, and whether it can maintain funding through the long development cycle. Outcomes could vary widely, which is typical for a small, innovative oncology company at this stage.

NEWS

November 26, 2025 · 4:05 PM UTC

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Read more

November 25, 2025 · 8:00 AM UTC

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Read more

November 19, 2025 · 9:00 AM UTC

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

Read more

November 5, 2025 · 8:30 AM UTC

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

Read more